secwatch.observer — SEC 8-K summary
======================================

Issuer:     Veradermics, Inc (MANE)
CIK:        0001827635
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001628280-26-027354
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Veradermics' VDPHL01 meets all primary and key secondary endpoints in Phase 2/3 male hair loss trial
--------------------------------------------------------------------------------

- VDPHL01 achieved mean TAHC increase of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID) vs 7.3 for placebo at Month 6 (p<0.0001)
- 79.3% (QD) and 86.0% (BID) of patients reported improvement on AAIRS vs 35.6% placebo
- No treatment-related serious adverse events or cardiac adverse events of special interest observed
- Statistically significant separation from placebo observed as early as Month 2

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/0001628280-26-027354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/mane-20260427.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-027354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer